HuMab-GD2 (MabVax)

N/A

Report date: 2025/03/20 16:01:41

Base Information

Drug NameHuMab-GD2 (MabVax)

Drug Alias Name31F9/1B7 GD2 antibody (MabVax Therapeutics Holdings)human mAb 1B7 (MabVax Therapeutics Holdings)anti-GD2 mAb (MabVax Therapeutics Holdings)HuMab-GD2

ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionDisialoganglioside GD2 inhibitors

TargetsDisialoganglioside GD2

Therapy Area/IndicationsMelanomaNeuroblastomaSarcoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMabvax Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMabvax Therapeutics Holdings Inc

Inactive CompaniesMabvax Therapeutics Inc

Active IndicationsMelanomaNeuroblastomaSarcoma

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A